Peer Review channel feed

Just like start­ing over: Mod­er­na tees up an­oth­er CFO; Ge­of­frey Porges puts down his SVB pen to join Schrödinger

3 years ago

As Covid pro­gram ad­vances, Enan­ta's new CMO says it's not 'lim­it­ed to an­tivi­ral­s'; With all eyes on Gilead-part­nered can­cer drugs, Ar­cus brings med­ical chief on board

3 years ago

Astel­las taps sea­soned CMO amid shift to on­col­o­gy; Doug Man­ion steps in­to a new Are­na fol­low­ing $6.7B buy­out

3 years ago

For­mer eGe­n­e­sis CEO joins vTv as it tries to make a come­back; Ei­sai nabs Alzheimer’s com­mer­cial ex­ec amid lecanemab push

3 years ago

Ex-Mod­er­na com­mer­cial leader lands at Cel­sion as CEO; Schwan song: Chang­ing of the guard at Roche to take ef­fect next year

3 years ago

For­mer Spark ex­ec to lead a gene ther­a­py up­start of his own; Big Phar­ma mar­ket­ing vet named CEO of Swiss biotech

3 years ago

En­tos lures for­mer Plexxikon CEO to guide push to­ward the clin­ic; Ex-Bris­tol My­ers im­munol­o­gy chief finds new home

4 years ago

Swat­ting away a takeover at­tempt, Zymeworks keeps re­tool­ing staff; Af­ter Cyg­nal-ing her ex­it from Flag­ship, Pearl Huang starts afresh

4 years ago

Af­ter sev­en months of search­ing, Lan­dos hires a CEO; Mar­ty Du­vall re-emerges from ill-fat­ed On­copep­tides tenure

4 years ago

As law­suit car­ries on against Guardant Health, CFO shake­up hits Il­lu­mi­na; Pfiz­er-backed biotech taps CEO to lead pur­suit of gene ther­a­py 2.0

4 years ago

Amarin fish­es for an­oth­er CFO as down­siz­ing takes hold; Cure­Vac makes a deal, then lines up No­var­tis ex­ec to lead de­vel­op­ment

4 years ago

Time Pas­sages: Bruce Gold­smith out at Jim Wilson's gene ther­a­py biotech; Flag­ship re­veals Michael Sev­eri­no’s CEO gig

4 years ago

Al­ways chas­ing the newest sci­ence, Schond Green­way joins MindMed; Mi­rati fills key va­can­cy with ex-Are­na fi­nance chief

4 years ago

Ex-Take­da ex­ec hits the ground run­ning at the helm of rare dis­ease biotech — with 3 pri­or­i­ties off the bat; Sea­soned CEO jumps to ALS up­start

4 years ago

Hel­lo, I must be go­ing: Jorge Gomez is Mod­er­na CFO for on­ly a day; As set­backs mount, In­ovio’s Joseph Kim choos­es the ex­it ramp

4 years ago

With Aduhelm in tat­ters, the search is on for Michel Vounatsos' re­place­ment at Bio­gen; David Liu, Roger Perl­mut­ter join in­sitro's SAB

4 years ago

‘Nat­ur­al evo­lu­tion’: Caris­ma’s sci­en­tif­ic co-founder moves in­to the CSO post; Vas Narasimhan en­lists Ron­ny Gal to help with No­var­tis re­vamp

4 years ago

Mov­ing on from Us­ama Ma­lik's in­sid­er trad­ing im­broglio, Fore re­sets at the top; Take­da spin­out turns to Neu­rana CEO to lead the way

4 years ago

Let’s build some­thing to­geth­er: Ex-Lowe’s CFO to join Pfiz­er while Mod­er­na’s David Meline re­tires; The CEO-part­ner par­ty rolls on at Flag­ship

4 years ago

Xeno­trans­plant gene ed­i­tor eGe­n­e­sis snags trans­plant ex­pert as CMO; John Tsai, Su­sanne Schaf­fert among the hard cuts made at No­var­tis

4 years ago

Changes in high-rank­ing ex­ecs poised to deep­en at Karyopharm; Till­man Gern­gross-chaired biotech pro­motes new med­ical chief to CEO

4 years ago

Roger Perl­mut­ter lures Roy Baynes away from Mer­ck; Now, Voy­ager: Al San­drock be­comes a CEO af­ter break from Bio­gen

4 years ago

Zai Lab gives Josh Smi­ley a sec­ond chance in a prime role; De­nali gets ready to re­arrange staff as clin­i­cal hold con­tin­ues

4 years ago

Centes­sa gives An­toine Yver a new role, brings his old col­league on board; Pre­lude to a change: Jane Huang sets up her next move

4 years ago
First page Previous page 45678910 Next page Last page
A service from the Financial Times